Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Baylor Research Institute.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Baylor University
Emory University
University of Southern California
Mayo Clinic
New York Presbyterian Hospital
Oregon Health and Science University
New York University
University of Cincinnati
University of Alabama at Birmingham
University of Texas
University of Chicago
University of California, San Francisco
Medical University of South Carolina
University of Virginia
Lahey Clinic
University of Medicine and Dentistry of New Jersey
Northwestern Memorial Hospital
Information provided by:
Baylor Research Institute
ClinicalTrials.gov Identifier:
NCT00163657
First received: September 9, 2005
Last updated: October 14, 2009
Last verified: October 2009
  Purpose

The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.


Condition Intervention Phase
Liver Transplantation
Drug: Daclizumab
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among Three Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

Resource links provided by NLM:


Further study details as provided by Baylor Research Institute:

Primary Outcome Measures:
  • Freedom from acute rejection at 12 months
  • Freedom from hepatitis C virus (HCV) recurrence at 12 months
  • Freedom from treatment failure at 12 months

Secondary Outcome Measures:
  • To compare recurrence of HCV by hepatic histology, viral load and allograft biochemistry
  • To compare the frequency and severity of biopsy proven rejection
  • To compare patient survival and graft survival
  • To compare time to first allograft rejection
  • To compare time to recurrence of HCV
  • To compare maintenance doses of CellCept, Prograf, and corticosteroids and the cumulative doses of corticosteroids and CellCept

Estimated Enrollment: 312
Study Start Date: July 2002
Detailed Description:

End-stage liver disease due to Hepatitis C virus (HCV) infection is the most common reason for liver transplantation in the United States. Patients who have HCV will always carry the virus in their body. If patients respond to treatment, the virus is no longer active. This means that although the virus is still present, it is not currently causing damage to their liver.

Because recurrence of HCV is virtually universal in HCV positive transplant recipients and is associated with long term, possibly lethal complications, the search for the most appropriate therapies must also include methods to prevent or minimize recurrence or disease progression, if the goal of improving long term outcomes for these patients is to be achieved.

Corticosteroids and high doses of immunosuppressive agents have been associated with increased rates of HCV recurrence. Finding a regimen that provides adequate immunosuppression to prevent early and late rejection episodes, and minimizes steroid usage as well as high doses of other immunosuppressive agents is highly desirable.

This study is being conducted to determine the most effective immunosuppressive regimen that will prevent allograft rejection, minimize adverse events and at the same time, prevent or reduce the incidence of HCV recurrence following liver transplant.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures for the full 2 years.
  2. Patient is a recipient of a primary whole/split, cadaveric/living donor liver transplant for end stage chronic Hepatitis C.
  3. Patient is > age 18.
  4. Female patients of child bearing potential must have a negative urine or serum pregnancy test upon hospitalization or within 7 days prior to enrollment and have agreed to utilize effective birth control throughout the study as well as for 6 weeks following study completion.

Exclusion Criteria:

  1. Patient has previously received or is receiving an organ transplant other than a liver.
  2. Patient has received a liver transplant from a Hepatitis B core antibody or a Hepatitis C antibody positive donor.
  3. Patient has received an ABO incompatible donor liver.
  4. Patient has fulminant liver failure with a life expectancy without a liver transplant of less than 7 days as defined by UNOS (Adult Patient Status 1, UNOS Policy 3.6.4.1: See Appendix C).
  5. Patient has renal dysfunction pre-transplant that, in the opinion of the investigator, will prohibit the use of calcineurin inhibitors within 72 hours post transplant.
  6. Patient is intubated, on vasopressors, is ICU bound, or has experienced a significant blood loss (greater than 5 units) 72 hours prior to transplant procedure.
  7. Recipient or donor is seropositive for human immunodeficiency virus (HIV) or HbsAg positive serology.
  8. Patient is to receive antilymphocyte antibody induction therapy, such as ATGAM (lymphocyte immune globulin), OKT3 (muromonab-CD3), Simulect (basiliximab), or Thymoglobulin.
  9. Patient has a known hypersensitivity to Prograf, HCO-60, CellCept, Zenapax or corticosteroids.
  10. Patient is pregnant or lactating.
  11. Patient has participated in a blinded trial or participated in a trial involving a non-marketed (investigational) drug within 3 months of enrollment.
  12. Patient has participated in a trial involving a market drug within 30 days. However, patients who participated in any interferon or ribavirin trials are permitted.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163657

Locations
United States, Texas
Baylor Regional Transplant Institute - Baylor University Medical Center
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Baylor Research Institute
Baylor University
Emory University
University of Southern California
Mayo Clinic
New York Presbyterian Hospital
Oregon Health and Science University
New York University
University of Cincinnati
University of Alabama at Birmingham
University of Texas
University of Chicago
University of California, San Francisco
Medical University of South Carolina
University of Virginia
Lahey Clinic
University of Medicine and Dentistry of New Jersey
Northwestern Memorial Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00163657     History of Changes
Other Study ID Numbers: 02-01-L, ZEN159
Study First Received: September 9, 2005
Last Updated: October 14, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Baylor Research Institute:
Hepatitis C Virus
Immunosuppressive Agents

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Liver Diseases
Hepatitis C, Chronic
End Stage Liver Disease
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Liver Failure
Hepatic Insufficiency
Immunosuppressive Agents
Daclizumab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014